Drug resistance in chemotherapy treatment

One obstacle to success with chemotherapy treatment is drug resistance. Patients receiving chemotherapy can develop resistance to previously effective drugs to the point that the drugs are no longer effective. Resistance – also called tachyphylaxis – occurs when a cancer cell develops the ability to keep the chemotherapy drug from entering it, or at least reduce the amount that can enter to a level that does not cause damage.

Cancer cells accomplish this phenomenon by emitting a substance called p-glycoprotein, which can remove the chemotherapy drug from the cancer cell. This process self-adjusts over time, with the cancer cells emitting more p-glycoprotein in each exposure to chemotherapy until resistance is established. The point in treatment at which resistance occurs is largely dependent on the type of cancer being treated, and can be at any time from the very beginning throughout the treatment schedule.

Working with one form of lung cancer, Israeli researcher Yosef Yarden found how malignancies develop resistance.  This lung cancer responded to initial chemotherapy treatment and appeared to go into complete remission before reappearing in patients months later.   The second coming of the cancer resisted chemotherapy.  Yarden’s researchers found the cancer ” rewired a main internal communications line” and produced new receptors that responded to growth signals but not to the chemotherapy agent.  It’s almost like the cancer is clever and has a mind of its own.

Chemotherapy drugs that are most often associated with resistance include paclitaxel, docetaxel, vinorelbine, vincristine, vinblastine, doxorubicin, daunorubicin, epirubicin, etoposide, teniposide, topotecan, dactinomycin, and mitomycin C. These drugs are used to treat a wide variety of cancers – solid tumors to lymphoma. These drugs also come from several different families of chemotherapy drugs, so the phenomenon of drug resistance is not confined to one family of cancer drugs or one type of cancer.

In order to combat resistance, chemotherapy drugs are often given in combination in the hopes that the cancer will fail to resist at least one of the drugs in the combination. Once a cancer has developed resistance to one type of drug, it is more likely to develop resistance to other drugs, making treatment more difficult. This is why it is important to determine the best possible drug combination and to use it first when the probability of resistance is lowest.  Another interesting method of emerging interest – though it is not yet used widely – is administering the chemotherapy drug on a long regimen of low doses.

Research is ongoing as scientists try to find a way to combat resistance. European researchers are studying the action of an enzyme called TAK-1 as it relates to extreme resistance found in pancreatic cancer. A substance was developed that inhibits the TAK-1 enzyme, and when this substance was given to mice along with the usual resistance-prone drugs, significant tumor reduction was observed. Other research is focusing on a substance called tariquidar, which attaches itself to the p-glycoprotein, hindering its ability to remove chemotherapy drugs from the cancer cell.

Resistance is one reason for remission in cancer cases.